{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-24-008118","form_type":"8-K","ticker":"PHIO","cik":"0001533040","company_name":"Phio Pharmaceuticals Corp.","filed_at":"2024-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.716738+00:00","generated_at":"2026-05-30T00:26:41.397983+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Phio Pharma Q3 net loss $1.5M, cash $5.4M; PH-762 shows complete response in one patient","bullets":["Net loss narrowed to $1.5M for Q3 2024 vs $2.8M in Q3 2023; R&D expenses fell 64% to $0.6M.","Cash at Sept 30, 2024 was $5.4M, down from $8.5M at Dec 31, 2023.","Phase 1b of PH-762: second cohort enrolled; one complete response (100% tumor clearance) and one partial response (90%) in cutaneous squamous cell carcinoma.","Warrant inducement exercise in July 2024 raised net proceeds of ~$2.6M.","Third cohort screening opens Dec 10, 2024; sixth clinical site added in San Diego."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-24-008118","json":"https://secwatch.observer/filing/0001683168-24-008118.json","markdown":"https://secwatch.observer/filing/0001683168-24-008118.md","text":"https://secwatch.observer/filing/0001683168-24-008118.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533040/000168316824008118/0001683168-24-008118-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533040/000168316824008118/phio_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:26:41.397983+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}